Liminatus Pharma, Inc. (LIMNW) revenue by segment

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

Liminatus Pharma, Inc. revenue by segment

Liminatus Pharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.